Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Lobular carcinoma of the breast with gastrointestinal metastasis.

Jones C, Tong AW, Mir M, Coyle Y.

Proc (Bayl Univ Med Cent). 2015 Jan;28(1):50-3.

2.

Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome.

Jones C, Levy Y, Tong AW.

BMJ Case Rep. 2014 Dec 1;2014. pii: bcr2014205663. doi: 10.1136/bcr-2014-205663.

3.

Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.

Robinson S, Levy Y, Maisel C, Tong AW.

BMJ Case Rep. 2014 Apr 12;2014. pii: bcr2014203894. doi: 10.1136/bcr-2014-203894.

4.

Oncolytic viruses for induction of anti-tumor immunity.

Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J.

Curr Pharm Biotechnol. 2012 Jul;13(9):1750-60. Review.

PMID:
21740355
5.

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.

Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C, Kumar P, Pappen BO, Rao DD, Templeton NS, Daniels EQ, Webb C, Monsma D, Scott S, Dylewski D, Frieboes HB, Brunicardi FC, Senzer N, Maples PB, Nemunaitis J, Tong AW.

DNA Cell Biol. 2011 Sep;30(9):715-26. doi: 10.1089/dna.2011.1240. Epub 2011 May 25.

PMID:
21612405
6.

Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.

Nemunaitis G, Jay CM, Maples PB, Gahl WA, Huizing M, Yardeni T, Tong AW, Phadke AP, Pappen BO, Bedell C, Allen H, Hernandez C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J.

Hum Gene Ther. 2011 Nov;22(11):1331-41. doi: 10.1089/hum.2010.192. Epub 2011 Apr 25.

7.

Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy.

Nemunaitis G, Maples PB, Jay C, Gahl WA, Huizing M, Poling J, Tong AW, Phadke AP, Pappen BO, Bedell C, Templeton NS, Kuhn J, Senzer N, Nemunaitis J.

J Gene Med. 2010 May;12(5):403-12. doi: 10.1002/jgm.1450.

PMID:
20440751
8.

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, Pappen B, Burke J, Ichimaru D, Urata Y, Fujiwara T.

Mol Ther. 2010 Feb;18(2):429-34. doi: 10.1038/mt.2009.262. Epub 2009 Nov 24.

9.

Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2.

Phadke AP, Jay C, Chen SJ, Haddock C, Wang Z, Yu Y, Nemunaitis D, Nemunaitis G, Templeton NS, Senzer N, Maples PB, Tong AW, Nemunaitis J.

Gene Regul Syst Bio. 2009 May 8;3:89-101.

10.

Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.

Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW.

Clin Cancer Res. 2009 Aug 1;15(15):4847-56. doi: 10.1158/1078-0432.CCR-09-0451. Epub 2009 Jul 21.

11.

Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.

Tong AW, Jay CM, Senzer N, Maples PB, Nemunaitis J.

Curr Gene Ther. 2009 Feb;9(1):45-60. Review.

PMID:
19275571
12.

Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.

Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, Chang D, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW.

Clin Cancer Res. 2009 Feb 15;15(4):1317-25. doi: 10.1158/1078-0432.CCR-08-1360.

13.

MicroRNA profile analysis of human prostate cancers.

Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J.

Cancer Gene Ther. 2009 Mar;16(3):206-16. doi: 10.1038/cgt.2008.77. Epub 2008 Oct 24.

PMID:
18949015
14.

Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

Tong AW, Nemunaitis J.

Cancer Gene Ther. 2008 Jun;15(6):341-55. doi: 10.1038/cgt.2008.8. Epub 2008 Mar 28. Review.

PMID:
18369380
15.

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.

Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, Sands B, Maples P, Tong AW.

Cancer Gene Ther. 2007 Nov;14(11):885-93. Epub 2007 Aug 17.

PMID:
17704755
16.

miRNA profiling for diagnosis and prognosis of human cancer.

Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW.

DNA Cell Biol. 2007 May;26(5):293-300. Review.

PMID:
17504025
17.

Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.

Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW.

Cancer Res. 2006 Oct 1;66(19):9736-43.

18.

Small RNAs and non-small cell lung cancer.

Tong AW.

Curr Mol Med. 2006 May;6(3):339-49. Review.

PMID:
16712479
19.

Small interfering RNA for experimental cancer therapy.

Tong AW, Zhang YA, Nemunaitis J.

Curr Opin Mol Ther. 2005 Apr;7(2):114-24. Review.

PMID:
15844618
20.

Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression.

Konduri K, Sahota SS, Babbage G, Tong AW, Kumar P, Newman JT, Stone MJ.

Clin Lymphoma. 2005 Mar;5(4):285-9.

PMID:
15794867
21.

Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.

Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S.

Mol Ther. 2005 Jan;11(1):160-72.

22.

Potential clinical application of antioncogene ribozymes for human lung cancer.

Tong AW, Zhang YA, Cunningham C, Maples P, Nemunaitis J.

Clin Lung Cancer. 2001 Feb;2(3):220-6.

PMID:
14700482
23.

Human monoclonal macroglobulins with antibody activity.

Stone MJ, McElroy YG, Pestronk A, Reynolds JL, Newman JT, Tong AW.

Semin Oncol. 2003 Apr;30(2):318-24.

PMID:
12720161
24.

Prospects for CD40-directed experimental therapy of human cancer.

Tong AW, Stone MJ.

Cancer Gene Ther. 2003 Jan;10(1):1-13. Review.

PMID:
12489023
25.

Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.

Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ.

Clin Cancer Res. 2001 Mar;7(3):691-703.

26.

Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.

Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW.

Gene Ther. 2000 Dec;7(23):2041-50.

27.

Cellular immune profile of patients with advanced cancer before and after taxane treatment.

Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, Nemunaitis J.

Am J Clin Oncol. 2000 Oct;23(5):463-72.

PMID:
11039505
28.

Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.

Zhang YA, Nemunaitis J, Tong AW.

Mol Biotechnol. 2000 May;15(1):39-49.

PMID:
10911621
29.

CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells.

Tong AW, Seamour B, Chen J, Su D, Ordonez G, Frase L, Netto G, Stone MJ.

Leuk Lymphoma. 2000 Feb;36(5-6):543-58.

PMID:
10784400
30.

Anti-K-ras1 Ribozyme Adenoviral Vector for Gene Therapy of Non-Small Cell Lung Cancer.

Zhang YA, Nemunaitis J, Tong AW.

Methods Mol Med. 2000;35:261-71. doi: 10.1385/1-59259-086-1:261.

PMID:
21390810
31.

Phenotypic and genotypic alterations characterize patients bearing plasma cell dyscrasias with a high M-component.

Greco C, Ameglio F, Alvino F, Mosiello A, Cianciulli AM, Venturo I, Del Monte G, Giampaolo M, Tong AW, Gandolfo GM.

Cell Prolif. 1999 Aug;32(4):231-8.

32.

Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma.

Tong AW, Su D, Mues G, Tillery GW, Goldstein R, Klintmalm G, Stone MJ.

Clin Cancer Res. 1996 Mar;2(3):531-9.

33.

CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity.

Tong AW, Stone MJ.

Leuk Lymphoma. 1996 Mar;21(1-2):1-8. Review.

PMID:
8907262
34.

Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro.

Tong AW, Zhang BQ, Mues G, Solano M, Hanson T, Stone MJ.

Blood. 1994 Nov 1;84(9):3026-33.

PMID:
7524765
35.

Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.

Tong AW, Huang YW, Zhang BQ, Netto G, Vitetta ES, Stone MJ.

Anticancer Res. 1993 May-Jun;13(3):593-7.

PMID:
8391243
36.

Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.

Huang YW, Richardson JA, Tong AW, Zhang BQ, Stone MJ, Vitetta ES.

Cancer Res. 1993 Mar 15;53(6):1392-6.

37.

Elimination of chemoresistant myeloma clonogenic cells from human bone marrow by monoclonal antibody and complement.

Tong AW, Dalton WS, Tsuruo T, Fay JW, Stone MJ.

Prog Clin Biol Res. 1990;333:155-64.

PMID:
2308979
38.

Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.

Tong AW, Lee J, Wang RM, Dalton WS, Tsuruo T, Fay JW, Stone MJ.

Cancer Res. 1989 Sep 1;49(17):4829-34. Erratum in: Cancer Res 1990 Jul 15;50(14):4451.

39.
40.
42.
43.

Discrimination of human small cell and non-small cell lung tumors by a panel of monoclonal antibodies.

Tong AW, Lee JC, Stone MJ.

J Natl Cancer Inst. 1986 Nov;77(5):1023-33.

PMID:
3022055
45.

Detection of antigen specific rosette formation with the FACS.

Tong AW, Vandenbark AA, Kraybill W, Regan D, Burger DR.

J Immunol Methods. 1983;56(1):63-74.

PMID:
6186743
46.
47.

Assessment of the mechanism of the leukocyte adherence inhibition test.

Tong AW, Burger DR, Finke P, Barney C, Vandenbark AA, Vetto RM.

Cancer Res. 1979 Feb;39(2 Pt 2):597-603.

Supplemental Content

Support Center